Skip to main content

Table 1 Currently active and ongoing clinical trials targeting the CD155/TIGIT axis

From: CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

Immunotherapy type

Immunotherapy targets

Disease

Treatment

Phase

Clinical trial identifier

Sponsor

Checkpoint inhibitor

CD155 (PVR), PD-1

Solid tumors

COM701, Opdivo (nivolumab)

1

NCT03667716

Compugen Ltd, Bristol-Myers Squibb

Oncolytic virus

CD155 (PVR)

Melanoma

PVSRIPO

1

NCT03712358

Istari Oncology, Inc., Duke University

Oncolytic virus

CD155 (PVR)

Glioblastoma, malignant glioma

PVSRIPO

1

NCT01491893

Istari Oncology, Inc., National Cancer Institute (NCI), Brain Tumor Research Charity Grant, Duke University

Monoclonal antibody

TIGIT, PD-1

Metastatic solid tumors

BGB-A1217, tislelizumab

1

NCT04047862

BeiGene

Monoclonal antibody

TIGIT, PD-L1

Non-small cell lung cancer

Atezolizumab, MTIG7192A

2

NCT03563716

Genentech, Inc.

Monoclonal antibody

TIGIT, PD-L1

Small cell lung cancer

Tiragolumab atezolizumab, carboplatin, etoposide

3

NCT04256421

Hoffmann-La Roche

Monoclonal antibody

TIGIT, PD-L1

Non-small cell lung cancer

Atezolizumab, tiragolumab

3

NCT04294810

Hoffmann-La Roche

Monoclonal antibody

TIGIT, PD-1

Solid tumors

AB154, AB122

1

NCT03628677

Arcus Biosciences, Inc.

Monoclonal antibody

TIGIT, PD-1, A2aR/A2bR

Non-small cell lung cancer

Zimberelimab, AB154, AB928

2

NCT04262856

Arcus Biosciences, Inc.

Monoclonal antibody

TIGIT, D-L1, MEK1/2, VEGFR2, CXCR4, DPP-4

Gastric adenocarcinoma, esophageal carcinoma

5-Fluorouracil (5-FU), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, PEGPH20, BL-8040, linagliptin, cisplatin, tiragolumab

1/2

NCT03281369

Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.